Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902500 | 1.00 | PRKCA (0.54) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL27216392 | 0.97 | MEN1 (0.52) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL27238682 | 0.97 | MEN1 (0.52) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL30902499 | 0.89 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL30902504 | 0.89 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL30902505 | 0.86 | PRKCA (0.57) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7755332 | 0.85 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL7755337 | 0.85 | PRKCA (0.59) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL30902501 | 0.84 | PRKCA (0.58) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18072622 | 0.84 | PRKCA (0.64) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189235-A1 | CATIONIC LIPIDS AND USES THEREOF | MELLO BIOTECH TAIWAN CO., LTD. (TW) | 2024-06-13 | — | — | US | disclosed |
| EP-4368609-A1 | CATIONIC LIPIDS AND USES THEREOF | Mello Biotech Taiwan Co., Ltd. (TW) | 2024-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189235-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, APOB, NPC1 | PRKCA 4100/4885PRKCE 4180/4885PRKCQ 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.